Why Is No One Taking Baby Aspirin for Heart Disease Prevention Anymore?

Key Points:

• The use of daily baby aspirin to prevent cardiovascular disease has declined significantly, dropping from 7.2% to 3.2% of adults aged 40 and older since 2018, according to data from Epic Research analyzing 279 million primary care visits.
• Changes in medical guidelines have influenced this trend, with the American College of Cardiology and American Heart Association advising against aspirin for primary prevention in most adults by 2019, and the USPSTF recommending adults 60 and older avoid starting aspirin in 2022.
• The shift is due to limited evidence supporting aspirin’s benefits for primary prevention and increased risks of bleeding and gastrointestinal side effects, alongside improved management of other cardiovascular risk factors like cholesterol and blood pressure.
• Experts agree that daily aspirin remains beneficial primarily for individuals with a history of cardiovascular events such as heart attack, stroke, or stent placement, while its use for others should be personalized based on individual risk assessments.
• Patients are encouraged to consult healthcare providers for tailored advice regarding aspirin use and cardiovascular disease prevention, as decisions depend on balancing cardiovascular risk against bleeding risk.